Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies

BACKGROUND: Surgical procedures impose hemostatic risk to people with hemophilia, which may be minimized by optimal factor (F) replacement therapy. METHODS: This analysis evaluates the efficacy and safety of extended half‐life factor replacement recombinant FVIII and FIX Fc fusion proteins (rFVIIIFc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chowdary, Pratima, Holmström, Margareta, Mahlangu, Johnny N., Ozelo, Margaret C., Pabinger, Ingrid, Pasi, K. John, Ragni, Margaret V., Shapiro, Amy, Barnowski, Chris, Lethagen, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326287/
https://www.ncbi.nlm.nih.gov/pubmed/35910942
http://dx.doi.org/10.1002/rth2.12760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326287/
https://www.ncbi.nlm.nih.gov/pubmed/35910942
http://dx.doi.org/10.1002/rth2.12760

Ejemplares similares